EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Do patients benefit from omega-3 fatty acids?

Samuel C R Sherratt iD, R Preston Mason iD, Peter Libby iD, Ph Gabriel Steg iD, Deepak L Bhatt iD

Cardiovascular Research · 17.02.2024 · 119 (18) · 2884-2901

DOI: 10.1093/cvr/cvad188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 22.01.2024. Verfasst von Samuel C R Sherratt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, USA. Hauptthemen laut MEDLINE: Fatty Acids, Omega-3, Cardiovascular Diseases. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV) health and elevated O3FA levels are associated with lower incident risk for CV disease (CVD.) Yet, treatment of at-risk patients with various O3FA formulations has produced disparate results in large, well-controlled and well-conducted clinical trials. Prescription formulations and fish oil supplements containing low-dose mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have routinely failed to prevent CV events in primary and secondary prevention settings when added to contemporary care, as shown most recently in the STRENGTH and OMEMI trials. However, as observed in JELIS, REDUCE-IT, and RESPECT-EPA, EPA-only formulations significantly reduce CVD events in high-risk patients. The CV mechanism of action of EPA, while certainly multifaceted, does not depend solely on reductions of circulating lipids, including triglycerides (TG) and LDL, and event reduction appears related to achieved EPA levels suggesting that the particular chemical and biological properties of EPA, as compared to DHA and other O3FAs, may contribute to its distinct clinical efficacy. In vitro and in vivo studies have shown different effects of EPA compared with DHA alone or EPA/DHA combination treatments, on atherosclerotic plaque morphology, LDL and membrane oxidation, cholesterol distribution, membrane lipid dynamics, glucose homeostasis, endothelial function, and downstream lipid metabolite function. These findings indicate that prescription-grade, EPA-only formulations provide greater benefit than other O3FAs formulations tested. This review summarizes the clinical findings associated with various O3FA formulations, their efficacy in treating CV disease, and their underlying mechanisms of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acids, Omega-3Cardiovascular DiseasesHumansEicosapentaenoic AcidDocosahexaenoic AcidsCholesterol

Stichwörter der Autor:innen

AtherosclerosisCardiovascular outcome trialsCholesterolDocosahexaenoic acidEicosapentaenoic acidEndothelial functionLipid oxidationOmega-3 fatty acids

Substanzen

Fatty Acids, Omega-3Eicosapentaenoic AcidDocosahexaenoic AcidsCholesterol

Autor:innen und Institutionen

  • Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH, USA.
  • Elucida Research LLC, Beverly, MA, USA.
  • Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Université Paris-Cité, INSERM_UMR1148/LVTS, FACT (French Alliance for Cardiovascular Trials), Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, NewYork 10029-5674, NY, USA.

ORCID-Profile: Samuel C R Sherratt, R Preston Mason, Peter Libby, Ph Gabriel Steg, Deepak L Bhatt

Zitieren

APA

Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2024). Do patients benefit from omega-3 fatty acids?. Cardiovascular Research, 119(18), 2884-2901. https://doi.org/10.1093/cvr/cvad188

Vancouver

Sherratt SCR, Mason RP, Libby P, Steg PG, Bhatt DL. Do patients benefit from omega-3 fatty acids?. Cardiovascular Research. 2024;119(18):2884-2901. doi:10.1093/cvr/cvad188

BibTeX
@article{Sherratt2024,
  author = {Sherratt, Samuel C R and Mason, R Preston and Libby, Peter and Steg, Ph Gabriel and Bhatt, Deepak L},
  title = {Do patients benefit from omega-3 fatty acids?},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {119},
  number = {18},
  pages = {2884--2901},
  doi = {10.1093/cvr/cvad188}
}
Kostenlos starten →